Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028151 | 1.00 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2TP53KMT2A | |
| SCHEMBL7591232 | 1.00 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2TP53KMT2A | |
| SCHEMBL2850903 | 0.95 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2TP53KMT2A | |
| SCHEMBL5926970 | 0.86 | FNTA (0.52) | NPC1RAB9ASMN1; SMN2TP53KMT2A | |
| SCHEMBL350064 | 0.85 | ITGB3 (0.62) | KMT2AMEN1MAPTITGB3ITGA2 | |
| SCHEMBL350063 | 0.85 | ITGB3 (0.62) | KMT2AMEN1MAPTITGB3ITGA2 | |
| SCHEMBL22995641 | 0.84 | MEN1 (0.61) | SMN1; SMN2KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL5027698 | 0.84 | MEN1 (0.61) | SMN1; SMN2KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL3717471 | 0.84 | MEN1 (0.61) | SMN1; SMN2KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL8579762 | 0.83 | TDP1 (0.49) | NPC1KMT2AMEN1MAPTCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177181-B1 | SUBSTITUTED BICYCLIC COMPOUNDS | AVENTIS PHARMA LTD (GB) | 2009-01-28 | — | — | EP | disclosed |
| US-6562851-B2 | Antiinflammatory and antiasthmatic agents; inhibitors of alpha4 beta1 mediated cell adhesion | AVENTIS PHARMA LIMITED (GB) | 2003-05-13 | — | — | US | disclosed |
| US-20020156111-A1 | Substituted bicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156111-A1 | Substituted bicyclic compounds | VCAM1, ITGA1, ITGA5 | NPC1 1064/4885RAB9A 3240/4885SMN1; SMN2 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.